Loading clinical trials...

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform | Clinical Trials | Clareo Health

RECRUITING

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform. An International, Multicenter, Prospective, and Retrospective Data Collection

NCT04927156•Balt Extrusion

View on ClinicalTrials.gov

Summary

BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices. This platform is purely exploratory, without hierarchical order of the objectives and associated outcomes.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Provision of a signed, written and dated informed consent or non-opposition (where applicable)

Exclusion Criteria

•Device(s) used in multiple procedures (two, or more, pathologies treated during the same procedure)
•Contra-indications of each device as described in the instructions for use.

Locations (12)

CHU Angers

Angers, France

Chu Bordeaux

Bordeaux, France

CHU Grenoble Alpes

La Tronche, France

Hôpital Roger Salengro

Lille, France

Kremlin Bicêtre - APHP

Paris, France

Chu Tours

Tours, France

Halle

Halle, Germany

Hospital: Fundacion Jimenez Diaz

Madrid, Spain

Hospital Clinico Universitario San Carlos

Madrid, Spain

Unversitario Central de Asturias

Oviedo, Spain

Key Dates

Start Date

July 12, 2021

Primary Completion Date

June 1, 2041

Completion Date

October 1, 2041

Last Updated

September 18, 2025

Enrollment

10,000

ESTIMATED participants

Conditions

Intracranial AneurysmBrain Arterial DiseaseAcute Ischemic StrokePeripheral Vascular DiseasesAVM - Cerebral Arteriovenous MalformationAVMFistulas Arteriovenous

Interventions

BALT medical devices

DEVICE

Contacts

Clinical Affairs Department

CONTACT

+33 1 39 89 46 41 Evidence@baltgroup.com

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

NCT07253181

Acute Ischemic StrokeLarge Vessel Occlusion+1 more

View study

RECRUITING

Targeting Real World Usage In Stroke Treatment

NCT07474935

Saccular and Fusiform AneurysmsPseudoaneurysm+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

Inclusion Criteria

Exclusion Criteria

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Targeting Real World Usage In Stroke Treatment

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke

Brain, Blood And Clot or Tissue Registry And Collaboration

Product Surveillance Registry